Curis Inc vs. Immunovant, Inc. Common Stock
Immunovant, Inc. Common Stock (IMVT) comes out ahead, leading on 3 of 5 compared factors.
Size & Scale
| CRIS | IMVT | |
|---|---|---|
| Market Cap | $7.83 million | $8.25 billion |
| Revenue (TTM) | $7.06 million | — |
| Net Income (TTM) | $-21,165,000 | $-538,217,000 |
CRIS and IMVT split the size & scale factors evenly.
Valuation
| CRIS | IMVT | |
|---|---|---|
| Price / Book | 0.62 | 11.22 |
| Price / Sales | 1.11 | — |
CRIS leads on 1 of 1 valuation factors.
Profitability
| CRIS | IMVT | |
|---|---|---|
| Net Margin | -299.66% | — |
| Return on Equity | -166.56% | -73.19% |
IMVT leads on 1 of 1 profitability factors.
Risk & Sentiment
| CRIS | IMVT | |
|---|---|---|
| Short Interest | 73.01% | 0.15% |
IMVT leads on 1 of 1 risk & sentiment factors.
Dig deeper: CRIS overview, CRIS financials, IMVT overview, IMVT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.